Clinical Trial Update: Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study [Phase 3]

View source ↗

Summary

An 8-week phase 3 pilot trial of cannabinoids for anxiety disorders was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder
• Social Anxiety Disorder

Snippet

Sponsor: McMaster University | Conditions: Generalized Anxiety Disorder, Social Anxiety Disorder | Phase 3 | Status: WITHDRAWN